Standard literature review lifecycle

Evidence Partners AI-Based SLR Platform Attracts $20 Million in Growth Financing

By MedTech Intelligence Staff
Standard literature review lifecycle

Double-digit growth of the company’s literature review software platform, DistillerSR, spurred $20 million in funding from the growth investment consortium led by Thomvest Ventures.

Evidence Partners, developer of AI-enabled literature review automation software and creator of DistillerSR, has closed a $20 million growth financing round led by Thomvest Ventures with participation from Pender Ventures and Export Development Canada (EDC). The funds will be used to accelerate global growth and hire additional product, engineering, sales, marketing and customer success talent.

Bootstrapped since its formation in 2008, Evidence Partners has been a pioneer in the development of AI-enabled literature review software through its DistillerSR platform, which has experienced double-digit growth since its launch in 2009. Today, more than 300 research organizations are using DistillerSR to produce transparent, audit-ready and regulatory compliant literature reviews.

“This new funding will allow us to further accelerate product innovation, enabling our customers to continue to bring life-changing medical products and research to market faster,” said Peter O’Blenis, CEO of Evidence Partners. “As the market leader for AI-enabled literature review software, the company will further invest in go-to-market initiatives to ensure that the global research community is aware of and can access this important technology.”

“The Evidence Partners team has built an industry-leading product and a global customer base of institutions and enterprises—all without external capital,” said Andrew Pinkerton, Partner at Thomvest Ventures, a cross-stage venture capital fund backed by Peter Thomson. “We are excited to partner with Evidence Partners as they enter their next phase of growth.”

Related Articles

About The Author

MedTech Intelligence